99 Wall Street, Suite 232, New York, NY 10005

Need Help? Call : (800) 991-3756

Class Action Cases

A class action has been filed on behalf of ZYNE Investors. Click "Join this Class Action" above.

Attorneys

Zynerba Pharmaceuticals, Inc.

Join Class Action »

Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) from March 11, 2019 through September 17, 2019 (the “Class Period”). The lawsuit seeks to recover damages for Zynerba Pharmaceuticals, Inc. investors under the federal securities laws.

If you bought Zynerba Pharmaceuticals, Inc. securities between March 11, 2019 through September 17, 2019, and would like to join the action, please click “Join This Class Action,” above.

Press Release

SHAREHOLDER ALERT: Zhang Investor Law Announces a Securities Class Action Lawsuit Against Zynerba Pharmaceuticals, Inc. – ZYNE 

New York, N.Y., October 27, 2019. Zhang Investor Law announcesa class action lawsuit on behalf of shareholders who bought shares of Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) between March 11, 2019 and September 17, inclusive (the “Class Period”).

To join the ZYNE class action, go to http://zhanginvestorlaw.com/cases/zynerba-pharmaceuticals-inc/ call Sophie Zhang, Esq. toll-free at 800-991-3756 or email info@zhanginvestorlaw.com for information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT.

According to the lawsuit, throughout the Class Period:  (1) Zygel was proving unsafe and not well-tolerated in the BELIEVE 1 Trial; (2) the foregoing created a foreseeable, heightened risk that Zynerba would fail to secure the necessary regulatory approvals for commercializing Zygel for the treatment of DEE in children and adolescents; and (3) as a result, Zynerba’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 23, 2019. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://zhanginvestorlaw.com/cases/zynerba-pharmaceuticals-inc/ or to discuss your rights or interests regarding this class action, please contact Sophie Zhang, Esq. of Zhang Investor Law toll free at 800-991-3756 or via e-mail at info@zhanginvestorlaw.com.

Zhang Investor Law represents investors worldwide.